We performed the same treatment on another orthotopic colorectal cancer model established with MC38 cells, a hypermutated cell line with missense mutations in Tp53, Braf, Pold1 and MMR gene Msh39,10, and a 74.3% tumor suppression rate (TSR%) was obtained after the same treatment (Supplementary Fig. 1a, b). This evidence concerns the gene MRC1 and colorectal cancer.